GlassScriptPhysician profile
Stuart W Schrader
NPI 1336173491
$11,947.07
in general payments reported to CMS, 2019-2025
75 companies · $2,320 in 2025
The $2,320 reported for 2025 was more than what 94% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,036 · 2020: $1,126 · 2021: $1,517 · 2022: $1,970 · 2023: $1,946 · 2024: $2,033 · 2025: $2,320.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,181 · Education: $118.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,180.61 |
| Education | $118.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $972.67 | 2021-2025 | Vraylar, Ubrelvy, Dalvance |
| Lilly USA, LLC | $922.63 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals LP | $867.09 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Amgen INC. | $764.12 | 2019-2025 | Otezla, Repatha, Otezla |
| Bayer Healthcare Pharmaceuticals INC. | $712.84 | 2021-2025 | |
| Novo Nordisk INC | $624.51 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $527.40 | 2019-2025 | |
| Teva Pharmaceuticals USA, INC. | $526.69 | 2023-2025 | Austedo Xr, Austedo Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $426.36 | 2020-2025 | Trintellix |
| Glaxosmithkline, LLC. | $425.27 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Supernus Pharmaceuticals, INC. | $406.61 | 2021-2024 | Qelbree, Qelbree, Xyosted |
| Corium, LLC | $291.34 | 2022-2025 | Azstarys |
| Ironshore Pharmaceuticals INC. | $273.16 | 2019-2024 | Jornay Pm |
| Abbott Laboratories | $269.09 | 2019-2025 | Freestyle Libre 3 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $237.10 | 2019-2025 | Relistor, Xifaxan |
Show all 75 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stuart Schrader listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.